Skip to main content

Animations

MJFF Publications

6431 - 6440 of 8801 Results
Title
Year
  • Year
  • 2023
  • 2025
  • 2025
  • 2019
  • 2018
  • 2021
  • 2019
  • 2017
  • 2024
  • 2022
  • Summary Details
    OPEN
    Title: Lifestyle factors and clinical severity of Parkinson’s disease
    Journal Name: Scientific Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41598-023-31531-w
    Citation Count: 12
  • Summary Details
    RESTRICTED
    Title: Effect of dopaminergic medications on Montreal Cognitive Assessment in Parkinson's disease patients
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2025.107951
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Use of Amplified Lewy Body Dementia Fibrils and Autoradiography to Characterize Binding of Radioligand Tg-1-90B to Alpha-Synuclein Fibrils in Postmortem Brain Tissue
    Journal Name: Cells
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/cells14181477
    Citation Count: 0
  • Summary Details
    RESTRICTED
    Title: Expert comment to: Novel Xp21.1 deletion associated with unusual features in large McLeod syndrome kindred
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2019.02.024
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Phosphorylation of Parkin at serine 65 is essential for its activationin vivo
    Journal Name: Open Biology
    Publisher: The Royal Society
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1098/rsob.180108
    Citation Count: 111
  • Summary Details
    RESTRICTED
    Title: Associations of sleep disorders with cerebrospinal fluid α-synuclein in prodromal and early Parkinson’s disease
    Journal Name: Journal of Neurology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/s00415-021-10812-2
    Citation Count: 24
  • Summary Details
    RESTRICTED
    Title: Single-pulse subthalamic deep brain stimulation reduces premotor-motor facilitation in Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2019.08.003
    Citation Count: 3
  • Summary Details
    OPEN
    Title: D‐512, a novel dopamine D2/3 receptor agonist, demonstrates greater anti‐Parkinsonian efficacy than ropinirole in Parkinsonian rats
    Journal Name: British Journal of Pharmacology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1111/bph.13937
    Citation Count: 23
  • Summary Details
    OPEN
    Title: Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
    Journal Name: Nature Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41591-024-03101-8
    Citation Count: 11
  • Summary Details
    OPEN
    Title: Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism
    Journal Name: Pharmacological Research
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.phrs.2022.106338
    Citation Count: 12
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.